You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/Refractory Hodgkin Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    National Research Center for Hematology
Dec 13, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

Non-hodgkin's Lymphoma Trial in Beijing (GNC-035)

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 27, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

Not yet recruiting
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
  • (no location specified)
Mar 23, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

Not yet recruiting
  • Lymphoma, Non-Hodgkin's, Adult
  • (no location specified)
Aug 4, 2023

Hodgkin's Lymphoma Trial in Milan (histone deacetylase inhibitor (ITF2357))

Terminated
  • Hodgkin's Lymphoma
  • histone deacetylase inhibitor (ITF2357)
  • Milan, Italy
    Istituto Nazionale per lo studio e la cura dei Tumori
Jan 18, 2022

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

    Enrolling by invitation
    • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Mar 22, 2023

    Non Hodgkin Lymphoma Trial in New York, Clayton, Frankston (IPH6501)

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • New York, New York
    • +2 more
    Oct 12, 2023

    Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

    Not yet recruiting
    • Classical Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • GEN3017
    • (no location specified)
    Aug 25, 2023

    Hodgkin Lymphoma Trial in Moscow (Nivolumab)

    Recruiting
    • Hodgkin Lymphoma
    • Moscow, Russian Federation
      The Federal Budget-Funded Institution National Medical Surgical
    Oct 31, 2022

    Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Duarte, Hackensack, Houston (SIRPant-M, External-beam

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • SIRPant-M
    • External-beam radiotherapy (XRT)
    • Duarte, California
    • +2 more
    Jul 21, 2023

    Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

    Not yet recruiting
    • Non-Hodgkin's Lymphoma, Relapsed
    • +2 more
    • (no location specified)
    Dec 6, 2022

    Hodgkin Lymphoma Trial in Salt Lake City (Axatilimab, Nivolumab)

    Not yet recruiting
    • Hodgkin Lymphoma
    • Salt Lake City, Utah
      Huntsman Cancer Institute at the University of Utah
    Feb 1, 2023

    Lymphoma, Non-Hodgkin Trial in Perth (DZD8586)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin
    • Perth, Western Australia, Australia
      Linear Clinical Research Ltd
    Apr 20, 2023